Targeting CDK4 in Melanoma

靶向黑色素瘤中的 CDK4

• 批准号: nhmrc : 1042986
• 负责人: Dr Karen Sheppard
• 金额: $ 48.1万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-cdk4-melanoma/111532
• 关键词: Targeting; CDK4; Melanoma

Major progress has been made in the treatment of cancer by the development of inhibitors of oncogenes that drive cancer growth. This application will test whether this approach can be used for melanomas with activation of the CDK4 oncogene that becomes activated in over 50% of melanomas. We will indentify which patients melanomas respond best to this approach and understand why some melanomas but not other responds providing the scientific framework for clinical trials of CDK4 inhibitors.

通过开发驱动癌症生长的癌基因抑制剂，在癌症治疗方面取得了重大进展。本申请将测试这种方法是否可用于具有CDK4癌基因激活的黑色素瘤，该癌基因在超过50%的黑色素瘤中被激活。我们将确定哪些黑色素瘤患者对这种方法的反应最好，并了解为什么有些黑色素瘤而不是其他黑色素瘤的反应，为CDK4抑制剂的临床试验提供科学框架。